MGMT immunohistochemistry (IHC) and exclusion of pancreatic NET (PanNET) patients from treatment with temozolomide-based therapy Meeting Abstract
| Authors: | Reidy, D. L.; Basturk, O.; Kriplani, A.; Abou-Alfa, G. K.; Jarnagin, W. R.; Allen, P. J.; Saltz, L.; Klimstra, D. S.; Zhang, L. Y. |
| Abstract Title: | MGMT immunohistochemistry (IHC) and exclusion of pancreatic NET (PanNET) patients from treatment with temozolomide-based therapy |
| Meeting Title: | 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 32 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2014 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2014-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358613200564 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2014.32.15_suppl.e15169 |
| Notes: | Meeting Abstract: e15169 -- Source: Wos |
